Brief: Scilex Holding Company Announces Filing Of A New Drug Submission To Health Canada
26/12/2023 16:02
Dec 26 (Reuters) - Scilex Holding Co SCLX.O :
* SCILEX HOLDING COMPANY ANNOUNCES FILING OF A NEW DRUG SUBMISSION (NDS) TO
HEALTH
CANADA’S PHARMACEUTICAL DRUGS DIRECTORATE, BUREAU OF CARDIOLOGY, ALLERGY AND
NEUROLOGICAL SCIENCES FOR THE APPROVAL OF ELYXYB® FOR ACUTE TREATMENT OF
MIGRAINE WITH OR WITHOUT AURA IN CANADA
* SCILEX HOLDING: ANTICIPATED TIMELINE FOR APPROVAL IN CANADA IS ABOUT 12
MONTHS
DEPENDING ON REVIEW CYCLES AND INFORMATION REQUESTS BY HEALTH CANADA.
Source text for Eikon: ID:nGNXb6YGdB
Further company coverage: SCLX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scilex Holding
See all newsEnters Promissory Note With Vivasor For Revolving Credit Up To $20 Million, On Aug 8
Brief: Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens To List On Biconomy Exchange As Early As June 23, 2026
Brief: O+C Private Credit Wade Defendants Dispute Complaint And Statement By Scilex Holding Company
Company Enters Binding Term Sheet With Datavault Ai - SEC Filing
Company May Offer Up To $500 Million In Securities - SEC Filing